Clinical Trial

HS-20089 in Patients With Ovarian Cancer and Endometrial Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated August 29, 2024 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
HS-20089 is an investigational antibody-drug conjugate (ADC) composed of a humanized IgG1 anti-B7-H4 monoclonal antibody conjugated to the topoisomerase I inhibitor payload via a protease-cleavable linker, with an average drug-to-antibody ratio of about 6. This is a phase 2, open-label, multi-center study to evaluate the efficacy, safety, pharmacokinetics (PK) and immunogenicity of HS-20089 as monotherapy in patients with recurrent or metastatic ovarian cancer and endometrial cancer.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-08-22; most recent amendment 2024-08-27.
Status change: Not Yet Recruiting → Recruiting 2024-04-01
Trial Details
NCT Number NCT06014190
Lead Sponsor Hansoh BioMedical R&D Company
Conditions Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Endometrial Cancer
Enrollment 460 participants
Start Date 2023-12-18
Primary Completion 2025-12-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-08-29